Norges Bank Acquires New Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Norges Bank acquired a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 314,800 shares of the company's stock, valued at approximately $3,472,000. Norges Bank owned approximately 0.59% of Stoke Therapeutics at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in shares of Stoke Therapeutics by 29.2% during the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after acquiring an additional 4,512 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Stoke Therapeutics during the fourth quarter worth $353,000. KLP Kapitalforvaltning AS bought a new position in shares of Stoke Therapeutics in the fourth quarter valued at $63,000. Teacher Retirement System of Texas bought a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $113,000. Finally, Swiss National Bank raised its holdings in shares of Stoke Therapeutics by 20.4% in the 4th quarter. Swiss National Bank now owns 67,300 shares of the company's stock worth $742,000 after acquiring an additional 11,400 shares during the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock worth $143,332 in the last quarter. Insiders own 11.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on STOK. Chardan Capital reissued a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.67.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK traded down $0.27 during mid-day trading on Wednesday, reaching $7.48. 23,052 shares of the company's stock were exchanged, compared to its average volume of 712,276. The firm has a 50-day moving average price of $8.07 and a two-hundred day moving average price of $10.46. The firm has a market capitalization of $404.56 million, a price-to-earnings ratio of -3.56 and a beta of 1.09. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.